cMyc Cancer Research Results

cMyc, cellular-MYC oncogene: Click to Expand ⟱
Source:
Type: oncogene
The MYC proto-oncogenes are among the most commonly activated proteins in human cancer. The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell. The c-Myc oncogene is a ‘master regulator’ of both cellular growth and metabolism in transformed cells.
-C-myc is a common oncogene that enhances aerobic glycolysis in the cancer cells by transcriptionally activating GLUT1, HK2, PKM2 and LDH-A

Inhibitors (downregulate):
Curcumin
Resveratrol: downregulate c-Myc expression.
Epigallocatechin Gallate (EGCG)
Quercetin
Berberine: decrease c-Myc expression and repress its transcriptional activity.
Scientific Papers found: Click to Expand⟱
5271- 3BP,    The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside
- Review, Var, NA
selectivity↑, selectivity↑, ATP↓, Glycolysis↓, HK2↓, mt-OXPHOS↓, GAPDH↓, mtDam↑, GSH↓, ROS↑, ER Stress↑, TumAuto↑, LC3‑Ⅱ/LC3‑Ⅰ↑, p62↓, Akt↓, HDAC↓, TumCA↑, Bcl-2↓, cMyc↓, Casp3↑, Cyt‑c↑, Mcl-1↓, PARP↓, ChemoSen↑,
3455- ALA,    Alpha-lipoic acid inhibits proliferation and migration of human vascular endothelial cells through downregulating HSPA12B/VEGF signaling axis
- in-vitro, Nor, HUVECs
*cMyc↓, *VEGF↓, *eNOS↓, angioG↓,
2639- Api,    Plant flavone apigenin: An emerging anticancer agent
- Review, Var, NA
*antiOx↑, *Inflam↓, AntiCan↑, ChemoSen↑, BioEnh↑, chemoPv↑, IL6↓, STAT3↓, NF-kB↓, IL8↓, eff↝, Akt↓, PI3K↓, HER2/EBBR2↓, cycD1/CCND1↓, CycD3↓, p27↑, FOXO3↑, STAT3↓, MMP2↓, MMP9↓, VEGF↓, Twist↓, MMP↓, ROS↑, NADPH↑, NRF2↓, SOD↓, COX2↓, p38↑, Telomerase↓, HDAC↓, HDAC1↓, HDAC3↓, Hif1a↓, angioG↓, uPA↓, Ca+2↑, Bax:Bcl2↑, Cyt‑c↑, Casp9↑, Casp12↑, Casp3↑, cl‑PARP↑, E-cadherin↑, β-catenin/ZEB1↓, cMyc↓, CDK4↓, CDK2↓, CDK6↓, IGF-1↓, CK2↓, CSCs↓, FAK↓, Gli↓, GLUT1↓,
2314- Api,    Apigenin Restrains Colon Cancer Cell Proliferation via Targeted Blocking of Pyruvate Kinase M2-Dependent Glycolysis
- in-vitro, Colon, HCT116 - in-vitro, Colon, HT29 - in-vitro, Colon, DLD1
Glycolysis↓, PKM2:PKM1↓, β-catenin/ZEB1↓, cMyc↓,
3391- ART/DHA,    Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
- Review, Var, NA
TumCP↓, TumMeta↓, angioG↓, TumVol↓, BioAv↓, Half-Life↓, BioAv↑, eff↑, eff↓, ROS↑, selectivity↑, TumCCA↑, survivin↓, BAX↑, Casp3↓, Casp8↑, Casp9↑, CDC25↓, CycB/CCNB1↓, NF-kB↓, cycD1/CCND1↓, cycE/CCNE↓, E2Fs↓, P21↑, p27↑, ADP:ATP↑, MDM2↓, VEGF↓, IL8↓, COX2↓, MMP9↓, ER Stress↓, cMyc↓, GRP78/BiP↑, DNAdam↑, AP-1↓, MMP2↓, PKCδ↓, Raf↓, ERK↓, JNK↓, PCNA↓, CDK2↓, CDK4↓, TOP2↓, uPA↓, MMP7↓, TIMP2↑, Cdc42↑, E-cadherin↑,
5380- ART/DHA,    Artemisinin and Its Derivatives as Potential Anticancer Agents
- Review, Var, NA
TumCG↓, angioG↓, Ferroptosis↑, TumCP↑, TumAuto↑, CSCs↑, eff↑, YAP/TEAD↓, TumCCA↑, ROS↑, ChemoSen↑, N-cadherin↓, Vim↓, MMP9↓, eff↑, STAT3↓, CD133↓, CD44↓, Nanog↓, cMyc↓, OCT4↓, Akt↓, mTOR↓,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
2320- ART/DHA,    Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis
- in-vitro, AML, K562 - in-vitro, Liver, HepG2
Glycolysis↓, GlucoseCon↓, lactateProd↓, GLUT1↓, PKM2↓, ECAR↓, LDHA↓, cMyc↓, other↝,
5415- ASA,    The Anti-Metastatic Role of Aspirin in Cancer: A Systematic Review
- Review, Var, NA
TumMeta↓, COX1↓, TXA2↓, AntiAg↑, EMT↓, TumCMig↓, TumCI↓, AMPK↑, cMyc↓, PGE2↓, Dose↑, RadioS↑, PD-L1↓, E-cadherin↑, EMT↓, Slug↓, Vim↓, Twist↓, MMP2↓, MMP9↓, other↑,
2388- Ash,    Withaferin A decreases glycolytic reprogramming in breast cancer
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468 - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-453
GlucoseCon↓, lactateProd↓, ATP↓, Glycolysis↓, GLUT1↓, HK2↓, PKM2↓, cMyc↓, Warburg↓, cMyc↓,
3167- Ash,    Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo
- in-vitro, MM, H226
TumCP↓, cMyc↓, cFos↓, cJun↓, TIMP2↑, Vim↓, ROS↑, BAX↑, IKKα↑, Casp3↑, cl‑PARP↑,
3162- Ash,    Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A
- Review, Var, NA
lipid-P↓, SOD↑, GPx↑, P53↑, Bcl-2↑, E6↓, E7↓, pRB↑, CycB/CCNB1↑, CDC2↑, P21↑, PCNA↓, ALDH1A1↓, Vim↓, Glycolysis↓, cMyc↓, BAX↑, NF-kB↓, Casp3↑, CHOP↑, DR5↑, ERK↓, Wnt↓, β-catenin/ZEB1↓, Akt↓, HSP90↓,
4816- ASTX,    Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
- in-vitro, Pca, NA
*antiOx↑, *Inflam↓, ChemoSen↑, E-cadherin↑, N-cadherin↓, VEGF↓, cMyc↓, PSA↓, cl‑Casp3↑, PARP1↑,
5250- Ba,    Exploring baicalein: A natural flavonoid for enhancing cancer prevention and treatment
- Review, Var, NA
Apoptosis↑, TumAuto↑, DNAdam↑, *antiOx↑, Inflam↓, PGE2↓, TumCCA↑, TumCMig↓, TumCI↓, angioG↓, selectivity↑, ChemoSen↑, HIF-1↓, cMyc↓, NF-kB↓, VEGF↓, P53↑, MMP2↓, CSCs↓, Bcl-xL↓, XIAP↓, survivin↓, tumCV↓, Casp3↑, Casp8↑, Bax:Bcl2↑, Akt↓, mTOR↓, PCNA↓, MMP↓, ROS↑, PARP↑, Casp9↑, BioAv↑, eff↑, P-gp↓, BioAv↑, selectivity↑,
2474- Ba,    Anticancer properties of baicalein: a review
- Review, Var, NA - in-vitro, Nor, BV2
ROS⇅, ROS↑, ER Stress↑, Ca+2↑, Apoptosis↑, eff↑, DR5↑, 12LOX↓, Cyt‑c↑, Casp7↑, Casp9↑, Casp3↑, cl‑PARP↑, TumCCA↑, cycE/CCNE↑, CDK4↓, cycD1/CCND1↓, VEGF↓, cMyc↓, Hif1a↓, NF-kB↓, BioEnh↑, BioEnh↑, P450↓, *Hif1a↓, *iNOS↓, *COX2↓, *VEGF↓, *ROS↓, *PI3K↓, *Akt↓,
2606- Ba,    Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma
- Review, HCC, NA
ChemoSen↑, TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, MMPs↓, MAPK↓, TGF-β↓, ZFX↓, p‑MEK↓, ERK↓, MMP2↓, MMP9↓, uPA↓, TIMP1↓, TIMP2↓, NF-kB↓, p65↓, p‑IKKα↓, Fas↑, Casp2↑, Casp3↑, Casp8↑, Casp9↑, Bcl-xL↓, BAX↑, ER Stress↑, Ca+2↑, JNK↑, P53↑, ROS↑, H2O2↑, cMyc↓, CD24↓, 12LOX↓,
2617- Ba,    Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review
- Review, Var, NA
Ca+2↑, MMP2↓, MMP9↓, Vim↓, Snail↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, i-ROS↑, Bcl-2↓, BAX↑, Cyt‑c↑, Casp3↑, Casp9↑, STAT3↓, IL6↓, MMP2↓, MMP9↓, NOTCH↓, PPARγ↓, p‑NRF2↓, HK2↓, LDHA↓, PDK1↓, Glycolysis↓, PTEN↑, Akt↓, Hif1a↓, MMP↓, VEGF↓, VEGFR2↓, TOP2↓, uPA↓, TIMP1↓, TIMP2↓, cMyc↓, TrxR↓, ASK1↑, Vim↓, ZO-1↑, E-cadherin↑, SOX2↓, OCT4↓, Shh↓, Smo↓, Gli1↓, N-cadherin↓, XIAP↓,
2626- Ba,    Molecular targets and therapeutic potential of baicalein: a review
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
AntiCan↓, *neuroP↑, *cardioP↑, *hepatoP↑, *RenoP↑, TumCCA↑, CDK4↓, cycD1/CCND1↓, cycE/CCNE↑, BAX↑, Bcl-2↓, VEGF↓, Hif1a↓, cMyc↓, NF-kB↓, ROS↑, BNIP3↑, *neuroP↑, *cognitive↑, *NO↓, *iNOS↓, *COX2↓, *PGE2↓, *NRF2↑, *p‑AMPK↑, *Ferroptosis↓, *lipid-P↓, *ALAT↓, *AST↓, *Fas↓, *BAX↓, *Apoptosis↓,
2615- Ba,    The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways
- Review, Var, NA
*AntiCan↓, *Inflam↓, TumCP↓, NF-kB↓, PPARγ↑, TumCCA↑, JAK2↓, STAT3↓, TumCMig↓, Glycolysis↓, MMP2↓, MMP9↓, selectivity↑, VEGF↓, Hif1a↓, cMyc↓, ChemoSen↑, ROS↑, p‑mTOR↓, PTEN↑,
5541- BBM,    Berbamine Suppresses the Growth of Gastric Cancer Cells by Inactivating the BRD4/c-MYC Signaling Pathway
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
TumCP↓, TumCCA↑, Apoptosis↑, BRD4↓, selectivity↑, TumCG↓, cMyc↓,
5542- BBM,    Pharmacological profiling of a berbamine derivative for lymphoma treatment
- vitro+vivo, lymphoma, NA
CaMKII ↓, TumCG↓, cMyc↓, ROS↑, UPR↑, ER Stress↑, PERK↑, BioAv↑, toxicity↓,
2021- BBR,    Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways
- Review, NA, NA
*antiOx?, *Inflam↓, Apoptosis↑, TumCCA↑, BAX↑, eff↑, VEGF↓, PI3K↓, Akt↓, mTOR↓, Telomerase↓, β-catenin/ZEB1↓, Wnt↓, EGFR↓, AP-1↓, NF-kB↓, COX2↑, NRF2↓, RadioS↑, STAT3↓, ERK↓, AR↓, ROS↑, eff↑, selectivity↑, selectivity↑, BioAv↓, DNMT1↓, cMyc↓,
1299- BBR,    Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review
- Review, NA, NA
TumCCA↑, TP53↑, COX2↓, Bax:Bcl2↑, ROS↑, VEGFR2↓, Akt↓, ERK↓, MMP2↓, MMP9↓, IL8↑, P21↑, p27↑, E-cadherin↓, Fibronectin↓, cMyc↓,
2706- BBR,    Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake
- in-vitro, HCC, Hep3B - in-vitro, HCC, Bel-7402 - in-vivo, NA, NA
TumCP↓, glut↓, SLC12A5↓, cMyc↓, GLS↓,
2712- BBR,    Suppression of colon cancer growth by berberine mediated by the intestinal microbiota and the suppression of DNA methyltransferases (DNMTs)
- in-vitro, Colon, HT29 - in-vivo, NA, NA
TumCG↓, GutMicro↑, other↝, IL10↓, cMyc↓, DNMT1↓, DNMTs↓,
5634- BCA,    Molecular Mechanisms of Biochanin A in AML Cells: Apoptosis Induction and Pathway-Specific Regulation in U937 and THP-1
- in-vitro, AML, U937 - in-vitro, AML, THP1
Apoptosis↑, Casp7↑, PARP1↑, Bcl-2↓, Myc↓, CHOP↑, P21↑, p62↑, TumCCA↑, TXNIP↑, ROS↑, *antiOx↑, *Inflam↓, *neuroP↑, AntiCan↑, TumCP↓, angioG↓, TumMeta↓, VEGF↓, MMPs↓, tumCV↓, DNAdam↑, CHOP↑, cMyc↓, BioAv↓, Half-Life↓, BioAv↑,
943- BetA,    Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
Glycolysis↓, lactateProd↓, GlucoseCon↓, ECAR↓, cMyc↓, LDHA↓, p‑PDK1↓, PDK1↓, Cav1↑, *Glycolysis↑, selectivity↑, OCR↓, OXPHOS↓,
2738- BetA,    Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, NA, NA
TumCI↓, TumCMig↓, Glycolysis↓, lactateProd↓, GRP78/BiP↑, ER Stress↑, PERK↑, p‑eIF2α↑, β-catenin/ZEB1↓, cMyc↓, ROS↑, angioG↓, Sp1/3/4↓, DNAdam↑, TOP1↓, TumMeta↓, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, LDHA↓, p‑PDK1↓, PDK1↓, ECAR↓, OCR↓, Hif1a↓, STAT3↓,
5721- BF,    Bufalin Suppresses Triple-Negative Breast Cancer Stem Cell Growth by Inhibiting the Wnt/β-Catenin Signaling Pathway
- in-vitro, BC, NA
CSCs↓, TumCCA↑, cMyc↓, cycD1/CCND1↓, CDK4↓, MMP↓, Casp↑, CD133↓, CD44↓, ALDH1A1↓, Nanog↓, OCT4↓, SOX2↓, Wnt↓, β-catenin/ZEB1↓, EGFR↓,
3525- Bor,    Synthesis of DNA-Boron Cluster Composites and Assembly into Functional Nanoparticles with Dual, Anti-EGFR, and Anti-c-MYC Oncogene Silencing Activity
- in-vitro, PC, PANC1
EGFR↓, cMyc↓,
1422- Bos,    Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family
- in-vitro, CRC, NA - in-vivo, NA, NA
5LO↓, TumCG↓, Let-7↑, miR-200b↑, NF-kB↓, cMyc↓, cycD1/CCND1↓, MMP9↓, CXCR4↓, VEGF↓, Bcl-xL↓, survivin↓, IAP1↓, XIAP↓, TumCG↓, CDK6↓, Vim↓, E-cadherin↑,
1426- Bos,  CUR,  Chemo,    Novel evidence for curcumin and boswellic acid induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer
- in-vivo, CRC, NA - in-vitro, CRC, HCT116 - in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vitro, RCC, SW-620 - in-vitro, RCC, HT-29 - in-vitro, CRC, Caco-2
miR-34a↑, miR-27a-3p↓, TumCG↓, BAX↑, Bcl-2↓, PARP1↓, TumCCA↑, Apoptosis↑, cMyc↓, CDK4↓, CDK6↓, cycD1/CCND1↓, ChemoSen↑, miR-34a↑, miR-27a-3p↓,
5695- BRU,    Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
- in-vitro, Lung, A549
NRF2↓, ChemoSen↑, Apoptosis↑, TumCP↓, TumCG↓, MRP1↓, GSH↓, cMyc↓,
5697- BRU,    Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma
- in-vitro, HNSCC, NA
NRF2↓, STAT3↓, proCasp3↑, cl‑PARP↑, Bcl-2↓, Bcl-xL↓, survivin↓, Hif1a↓, cMyc↓, JNK↑, MAPK↑, tumCV↓, ROS∅,
1640- CA,  MET,    Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1α-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines
- in-vitro, Cerv, SiHa
GLS↓, NADPH↓, ROS↑, TumCD↑, AMPK↑, Hif1a↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDH↓, cMyc↓, BAX↓, cycD1/CCND1↓, PDH↓, ROS↑, Apoptosis↑, eff↑, ACLY↓, FASN↓, Bcl-2↓, Glycolysis↓,
6002- CGA,    Chlorogenic Acid: A Systematic Review on the Biological Functions, Mechanistic Actions, and Therapeutic Potentials
- Review, Var, NA - Review, Diabetic, NA - Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*neuroP↑, *Inflam↓, *antiOx↑, *cardioP↑, *NRF2↑, *AMPK↑, *SOD↑, *Catalase↑, *GSH↑, *GPx↑, *ROS↓, *TNF-α↓, *IL6↓, *NF-kB↓, *COX2↓, *glucose↓, *TRPC1↓, *Ca+2↓, *HO-1↑, *NF-kB↓, *PPARα↝, *Hif1a↓, *JNK↓, *BP↓, *AntiDiabetic↑, *hepatoP↑, *TLR4↓, *NRF2↑, *Casp↓, *neuroP↑, *Aβ↓, *LDH↓, *MDA↓, *memory↑, *AChE↓, *eff↑, EMT↝, N-cadherin↓, E-cadherin↑, TumCCA↑, ROS↑, p‑P53↑, HO-1↑, NRF2↑, ChemoSen↑, mtDam↑, Casp3↑, Casp9↑, PARP↑, Bax:Bcl2↑, TumCG↓, cycD1/CCND1↓, cMyc↓, CDK2↓, mitResp↓, Glycolysis↓, Hif1a↓, PCNA↓, p‑GSK‐3β↓, VEGF↓, PI3K↓, Akt↓, mTOR↓, OS↑,
2781- CHr,  PBG,    Chrysin a promising anticancer agent: recent perspectives
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, eff↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2↓, NF-kB↓, PDK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB/CCNB1↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,
126- CUR,    Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, PC3 - in-vitro, Pca, DU145
miR-34a↑, β-catenin/ZEB1↓, cMyc↓, P21↑, cycD1/CCND1↓, PCNA↓, TumCG↓,
12- CUR,    Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells
- in-vitro, MB, DAOY
HH↓, Shh↓, Gli1↓, PTCH1↓, cMyc↓, n-MYC↓, cycD1/CCND1↓, Bcl-2↓, NF-kB↓, Akt↓, β-catenin/ZEB1↓, survivin↓, Apoptosis↑, ChemoSen↑, RadioS↑, eff↑,
165- CUR,    Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP
AR↓, β-catenin/ZEB1↓, p‑Akt↓, GSK‐3β↓, p‑β-catenin/ZEB1↑, cycD1/CCND1↓, cMyc↓, chemoPv↑, TumCP↓,
470- CUR,    Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line
- in-vitro, Ovarian, SKOV3
Wnt/(β-catenin)↓, EMT↓, DNMT3A↓, cycD1/CCND1↓, cMyc↓, Fibronectin↓, Vim↓, E-cadherin↑, SFRP5↑,
406- CUR,    Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2
- in-vitro, BC, MCF-7 - in-vitro, Hepat, HepG2
GSH↓, Apoptosis↑, Bcl-2↓, cMyc↓,
437- CUR,    Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids
- vitro+vivo, CRC, TCO1 - vitro+vivo, CRC, TCO2
cycD1/CCND1↓, cMyc↓, p‑ERK↓, CD44↓, CD133↓, LGR5↓, TumCCA↑, TumVol↓, CSCs↓,
4826- CUR,    The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management
- Review, Var, NA
*antiOx↑, *Inflam↑, *ROS↓, Apoptosis↑, TumCP↓, BioAv↓, Half-Life↓, eff↑, TumCCA↑, BAX↑, Bak↑, PUMA↑, BIM↑, NOXA↑, TRAIL↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, cMyc↓, Casp↑, NF-kB↓, STAT3↓, AP-1↓, angioG↓, TumMeta↑, VEGF↓, MMPs↓, DNMTs↓, HDAC↓, ROS↑,
4709- CUR,    Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways
- Review, Var, NA
miR-21↓, TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, miR-99↑, JAK↓, STAT↓, cycD1/CCND1↓, P21↑, ChemoSen↑, miR-192-5p↑, cMyc↓, Wnt↓, β-catenin/ZEB1↓, miR-130a↓,
1183- DHA,    Docosahexaenoic acid inhibited the Wnt/β-catenin pathway and suppressed breast cancer cells in vitro and in vivo
- in-vitro, BC, 4T1 - in-vitro, BC, MCF-7 - in-vivo, BC, NA
TumCG↓, TumCCA↑, β-catenin/ZEB1↓, TCF↓, LEF1↓, cMyc↓, cycD1/CCND1↓, Wnt/(β-catenin)↓, TumMeta↓,
1607- EA,    Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions
- Review, GC, NA
STAT3↓, TumCP↓, Apoptosis↑, NF-kB↓, EMT↓, RadioS↑, antiOx↑, COX1↓, COX2↓, cMyc↓, Snail↓, Twist↓, MMP2↓, P90RSK↓, CDK8↓, PI3K↓, Akt↓, TumCCA↑, Casp8↑, PCNA↓, TGF-β↓, Shh↓, NOTCH↓, IL6↓, ALAT↓, ALP↓, AST↓, VEGF↓, P21↑, *toxicity∅, *Inflam↓, *cardioP↑, *neuroP↑, *hepatoP↑, ROS↑, *NRF2↓, *GSH↑,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
1057- EDM,    Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion
NF-kB↓, TNF-α↓, COX2↓, cycD1/CCND1↓, cMyc↓, MMP9↓, ICAM-1↓, MDR1↓, XIAP↓, Bcl-2↓, Bcl-xL↓, IAP1↓, IAP2↓, cFLIP↓, Bfl-1↓,
22- EGCG,    Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics
- in-vitro, PC, CD133+ - in-vitro, PC, CD44+ - in-vitro, PC, CD24+ - in-vitro, PC, ESA+
HH↓, Smo↓, PTCH1↓, PTCH2↓, Gli1↓, GLI2↓, Gli↓, Bcl-2↓, XIAP↓, Shh↓, survivin↓, Casp3↑, Casp7↑, CSCs↓, Nanog↓, cMyc↓, OCT4↓, EMT↓, Snail↓, Slug↓, Zeb1↓, TumCMig↓, TumCI↓, eff↑,

Showing Research Papers: 1 to 50 of 122
Page 1 of 3 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 122

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   Ferroptosis↑, 2,   GPx↑, 1,   GSH↓, 3,   H2O2↑, 1,   HO-1↓, 1,   HO-1↑, 1,   HO-2↓, 1,   lipid-P↓, 1,   lipid-P↑, 1,   NRF2↓, 5,   NRF2↑, 1,   p‑NRF2↓, 1,   OXPHOS↓, 1,   mt-OXPHOS↓, 1,   ROS↓, 1,   ROS↑, 25,   ROS⇅, 1,   ROS∅, 1,   i-ROS↑, 1,   SOD↓, 1,   SOD↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 1,   AIF↑, 1,   ATP↓, 2,   mt-ATP↓, 1,   Bfl-1↓, 1,   CDC2↑, 1,   CDC25↓, 1,   p‑MEK↓, 1,   mitResp↓, 1,   MMP↓, 5,   mtDam↑, 2,   OCR↓, 2,   Raf↓, 1,   XIAP↓, 7,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 2,   ACLY↓, 1,   ALAT↓, 1,   AMPK↑, 2,   Cav1↑, 1,   cMyc↓, 50,   ECAR↓, 3,   ECAR↝, 1,   FASN↓, 1,   GAPDH↓, 1,   GLS↓, 2,   GlucoseCon↓, 4,   glut↓, 1,   Glycolysis↓, 13,   HK2↓, 4,   lactateProd↓, 5,   LDH↓, 1,   LDHA↓, 4,   NADPH↓, 1,   NADPH↑, 1,   PDH↓, 1,   PDK1?, 2,   PDK1↓, 4,   p‑PDK1↓, 2,   PDK3↑, 1,   PFK↓, 1,   PKM2↓, 3,   PKM2:PKM1↓, 1,   PPARγ↓, 1,   PPARγ↑, 1,   SIRT1↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 13,   Akt↑, 1,   p‑Akt↓, 3,   Apoptosis↑, 14,   ASK1↑, 1,   Bak↑, 1,   BAX↓, 1,   BAX↑, 9,   Bax:Bcl2↑, 5,   Bcl-2↓, 12,   Bcl-2↑, 1,   Bcl-xL↓, 7,   BIM↑, 1,   Casp↑, 3,   Casp12↑, 1,   Casp2↑, 1,   Casp3↓, 1,   Casp3↑, 11,   cl‑Casp3↑, 1,   proCasp3↑, 1,   Casp7↑, 3,   Casp8↑, 4,   Casp9↑, 8,   cFLIP↓, 1,   p‑Chk2↑, 1,   CK2↓, 1,   Cyt‑c↑, 5,   Diablo↑, 1,   DR5↑, 2,   Fas↑, 1,   Ferroptosis↑, 2,   IAP1↓, 2,   IAP2↓, 1,   iNOS↓, 1,   JNK↓, 1,   JNK↑, 2,   MAPK↓, 1,   MAPK↑, 1,   Mcl-1↓, 2,   MDM2↓, 2,   Myc↓, 2,   NOXA↑, 2,   oncosis↑, 1,   p27↑, 4,   p38↑, 1,   PUMA↑, 2,   survivin↓, 9,   Telomerase↓, 3,   TRAIL↑, 1,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

CaMKII ↓, 1,   HER2/EBBR2↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

BRD4↓, 1,   cJun↓, 1,   miR-192-5p↑, 1,   miR-21↓, 1,   miR-27a-3p↓, 2,   other↑, 1,   other↝, 2,   pRB↑, 1,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

CHOP↑, 3,   p‑eIF2α↑, 1,   ER Stress↓, 1,   ER Stress↑, 6,   GRP78/BiP↑, 2,   HSP90↓, 1,   PERK↑, 2,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

BNIP3↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   p62↓, 1,   p62↑, 1,   TumAuto↑, 4,  

DNA Damage & Repair ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↓, 1,   DNAdam↑, 5,   DNMT1↓, 2,   DNMT3A↓, 1,   DNMTs↓, 2,   HR↓, 1,   p16↑, 1,   P53↑, 4,   p‑P53↑, 1,   PARP↓, 1,   PARP↑, 2,   cl‑PARP↑, 5,   PARP1↓, 1,   PARP1↑, 2,   PCNA↓, 7,   RAD51↓, 1,   SIRT6↑, 1,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

BRD4↓, 1,   CDK2↓, 5,   CDK4↓, 6,   CycB/CCNB1↓, 2,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 19,   CycD3↓, 1,   cycE/CCNE↓, 2,   cycE/CCNE↑, 2,   cycE1↓, 1,   E2Fs↓, 1,   P21↑, 8,   p‑RB1↓, 1,   TumCCA↑, 21,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 2,   CD133↓, 3,   CD24↓, 1,   CD44↓, 3,   CDK8↓, 2,   cFos↓, 1,   cMET↓, 1,   CSCs↓, 5,   CSCs↑, 1,   EMT↓, 7,   EMT↝, 1,   ERK↓, 6,   p‑ERK↓, 2,   FOXO3↑, 1,   Gli↓, 2,   Gli1↓, 3,   GSK‐3β↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 3,   HDAC1↓, 1,   HDAC3↓, 1,   HH↓, 2,   IGF-1↓, 1,   Let-7↑, 1,   LGR5↓, 1,   miR-34a↑, 3,   miR-99↑, 1,   mTOR↓, 6,   p‑mTOR↓, 2,   n-MYC↓, 1,   Nanog↓, 3,   NOTCH↓, 3,   NOTCH1↑, 1,   OCT4↓, 4,   P90RSK↓, 1,   PI3K↓, 6,   PTCH1↓, 2,   PTCH2↓, 1,   PTEN↑, 3,   SFRP5↑, 1,   Shh↓, 4,   Smo↓, 2,   SOX2↓, 2,   STAT↓, 1,   STAT3↓, 12,   p‑STAT3↓, 1,   TCF↓, 1,   TOP1↓, 2,   TOP2↓, 2,   TumCG↓, 11,   Wnt↓, 5,   Wnt/(β-catenin)↓, 4,   ZFX↓, 1,  

Migration ⓘ

5LO↓, 1,   AntiAg↑, 1,   AP-1↓, 3,   Ca+2↑, 4,   Ca+2↝, 1,   Cdc42↑, 1,   CDK4/6↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 10,   FAK↓, 1,   p‑FAK↓, 2,   Fibronectin↓, 2,   GLI2↓, 1,   ITGB1↑, 1,   Ki-67↓, 1,   LEF1↓, 1,   miR-130a↓, 1,   miR-200b↑, 1,   MMP2↓, 13,   MMP7↓, 1,   MMP9↓, 13,   MMP9↑, 1,   MMPs↓, 3,   N-cadherin↓, 5,   NCAM↑, 1,   PKCδ↓, 2,   Rho↓, 1,   ROCK1↓, 1,   Slug↓, 2,   SMAD3↓, 1,   Snail↓, 4,   TGF-β↓, 4,   TIMP1↓, 2,   TIMP2↓, 2,   TIMP2↑, 3,   TumCA↑, 1,   TumCI↓, 6,   TumCMig↓, 7,   TumCP↓, 13,   TumCP↑, 1,   TumMeta↓, 6,   TumMeta↑, 1,   Twist↓, 4,   TXNIP↑, 1,   uPA↓, 5,   Vim↓, 9,   Zeb1↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 12,   p‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 10,   EGFR↓, 5,   Endoglin↑, 1,   HIF-1↓, 1,   Hif1a↓, 11,   KDR/FLK-1↓, 1,   NO↓, 1,   TXA2↓, 1,   VEGF↓, 17,   VEGFR2↓, 2,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT1↓, 5,   GLUT3↓, 1,   NHE1↓, 1,   P-gp↓, 1,   SLC12A5↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 3,   COX2↓, 7,   COX2↑, 1,   CXCR4↓, 1,   ICAM-1↓, 1,   IKKα↑, 1,   p‑IKKα↓, 1,   IL1↓, 1,   IL10↓, 1,   IL1β↓, 1,   IL2↑, 1,   IL6↓, 4,   IL8↓, 2,   IL8↑, 1,   Inflam↓, 2,   JAK↓, 2,   JAK2↓, 1,   MIP2↓, 1,   NF-kB↓, 18,   p65↓, 1,   PD-L1↓, 3,   PGE2↓, 3,   PSA↓, 1,   TNF-α↓, 3,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 3,   CDK6↓, 5,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 5,   BioAv↑, 6,   BioEnh↑, 3,   ChemoSen↑, 12,   Dose↑, 1,   Dose↝, 1,   Dose∅, 1,   eff↓, 1,   eff↑, 14,   eff↝, 1,   Half-Life↓, 4,   MDR1↓, 1,   MRP1↓, 1,   P450↓, 1,   RadioS↑, 6,   selectivity↑, 11,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AR↓, 3,   AST↓, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 5,   GutMicro↑, 1,   HER2/EBBR2↓, 1,   IL6↓, 4,   Ki-67↓, 1,   LDH↓, 1,   Myc↓, 2,   PD-L1↓, 3,   PSA↓, 1,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiCan↓, 1,   AntiCan↑, 2,   chemoPv↑, 2,   OS↑, 1,   toxicity↓, 1,   TumVol↓, 2,  
Total Targets: 364

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx?, 1,   antiOx↑, 6,   Catalase↑, 2,   Ferroptosis↓, 1,   GPx↑, 2,   GSH↑, 2,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 2,   NRF2↓, 1,   NRF2↑, 3,   ROS↓, 4,   SOD↑, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   AMPK↑, 1,   p‑AMPK↑, 1,   cMyc↓, 1,   glucose↓, 1,   Glycolysis↑, 1,   LDH↓, 1,   PPARα↝, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↓, 1,   BAX↓, 1,   Casp↓, 1,   Fas↓, 1,   Ferroptosis↓, 1,   iNOS↓, 2,   JNK↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↓, 1,  

Migration ⓘ

Ca+2↓, 1,   TRPC1↓, 1,  

Angiogenesis & Vasculature ⓘ

eNOS↓, 1,   Hif1a↓, 2,   NO↓, 1,   VEGF↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   IL6↓, 1,   Inflam↓, 8,   Inflam↑, 1,   NF-kB↓, 2,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   eff↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   BP↓, 1,   IL6↓, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

AntiCan↓, 1,   AntiDiabetic↑, 1,   cardioP↑, 3,   cognitive↑, 1,   hepatoP↑, 4,   memory↑, 1,   neuroP↑, 7,   RenoP↑, 1,   toxicity∅, 1,  
Total Targets: 62

Scientific Paper Hit Count for: cMyc, cellular-MYC oncogene
10 Curcumin
10 Quercetin
9 Thymoquinone
7 Resveratrol
6 Baicalein
4 Artemisinin
4 Berberine
4 Piperlongumine
4 Silymarin (Milk Thistle) silibinin
3 Ashwagandha(Withaferin A)
3 EGCG (Epigallocatechin Gallate)
3 Luteolin
3 Lycopene
2 Apigenin (mainly Parsley)
2 Berbamine
2 Betulinic acid
2 Boswellia (frankincense)
2 brusatol
2 Ellagic acid
2 Sulforaphane (mainly Broccoli)
2 Ferulic acid
2 Niclosamide (Niclocide)
2 Phenethyl isothiocyanate
2 Piperine
2 Pterostilbene
2 Ursolic acid
2 Vitamin K2
1 3-bromopyruvate
1 Alpha-Lipoic-Acid
1 Aspirin -acetylsalicylic acid
1 Astaxanthin
1 Biochanin A
1 Bufalin/Huachansu
1 Boron
1 Chemotherapy
1 Caffeic acid
1 Metformin
1 Chlorogenic acid
1 Chrysin
1 Propolis -bee glue
1 Docosahexaenoic Acid
1 Evodiamine
1 Genistein (soy isoflavone)
1 Fisetin
1 flavonoids
1 Galloflavin
1 Gambogic Acid
1 Honokiol
1 lambertianic acid
1 Magnetic Fields
1 Mushroom Chaga
1 Phenylbutyrate
1 Cisplatin
1 salinomycin
1 Shikonin
1 Aflavin-3,3′-digallate
1 triptolide
1 Urolithin
1 Vitamin C (Ascorbic Acid)
1 γ-Tocotrienol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:35  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page